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function (HR, 2.01; 95% CI, 1.21–3.34) was associated with 
 increased cardiovascular mortality risk after multivariable 
adjustment. Men with kidney dysfunction and low TT con-
centrations were identified as high-risk individuals showing 
a more than 2-fold increased all-cause mortality risk (HR, 
2.52; 95% CI, 1.08–5.85). Added to multivariable models, 
nonsignificant interaction terms suggest that kidney dys-
function and low TT are primarily additive rather than syner-
gistic mortality risk factors.  Conclusion: In the case of early 
loss of kidney function, measured TT concentrations might 
help to detect high-risk individuals for potential therapeutic 
interventions and to improve mortality risk assessment and 
outcome.  Copyright © 2011 S. Karger AG, Basel 
 Introduction 
 Chronic kidney disease (CKD) is a major and growing 
public health issue of considerable socioeconomic and 
medical importance. Increasing CKD prevalence and in-
cidence rates can be confirmed worldwide, reflecting sim-
ilar increases in shared cardiovascular disease (CVD) risk 
factors including obesity, diabetes mellitus, and hyperten-
sion  [1] . The associations of non-dialysis-dependent CKD 
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 Abstract 
 Background: Chronic kidney disease (CKD) and low serum 
total testosterone (TT) concentrations are independent pre-
dictors of mortality risk in the general population, but their 
combined potential for improved mortality risk stratification 
is unknown.  Methods: We used data of 1,822 men from the 
population-based Study of Health in Pomerania followed-
up for 9.9 years (median). The direct effects of kidney dys-
function (estimated glomerular filtration rate  ! 60 ml/min/
1.73 m 2 ), albuminuria (urinary albumin-creatinine ratio  6 2.5 
mg/mmol) and their combination (CKD) on all-cause and car-
diovascular mortality were analyzed using multivariable
Cox regression models. Serum TT concentrations below the 
age-specific 10th percentile (by decades) were considered 
low and were used for further risk stratification.  Results: Kid-
ney dysfunction (hazard ratio, HR, 1.40; 95% confidence in-
terval, CI, 1.02–1.92), albuminuria (HR, 1.38; 95% CI, 1.06–1.79), 
and CKD (HR, 1.42; 95% CI, 1.09–1.84) were associated with 
 increased all-cause mortality risk, while only kidney dys-
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with all-cause and cardiovascular mortality has been 
shown in different populations, age-groups, and study set-
tings  [2] , and were consolidated by a large meta-analysis of 
21 general population cohorts  [3] . Furthermore, even mild 
kidney dysfunction was identified to substantially in-
crease the risk of cardiovascular events, hospitalization, 
and death in a large community-based population  [4] .
 The altered metabolic milieu in CKD affects the secre-
tion of hormones and the hormone-induced response of 
target tissues, causing endocrine dysfunctions  [5] . As 
many as 50–70% of male patients with severe CKD may 
be hypogonadal on the basis of low concentrations of to-
tal and free testosterone  [6] . Furthermore, alterations of 
sex hormone production and metabolism are already 
seen when moderate reductions in the glomerular filtra-
tion rate arise  [7] . We have recently demonstrated that 
low concentrations of total testosterone (TT) were inde-
pendently associated with increased risk of all-cause and 
cardiovascular mortality in a population-based sample of 
1,954 men  [8] .
 Based on the interrelationship between CKD and TT, 
it is reasonable to expect an impact of low TT concentra-
tions on CKD-related mortality associations. But to date, 
there are only clinical studies reporting that low TT con-
centrations were associated with increased cardiovascu-
lar comorbidity and overall mortality risk in male end-
stage renal disease and dialysis patients  [9, 10] . Due to the 
lack of systematic investigations in larger population-
based samples, it is currently unknown whether a com-
bined assessment of CKD measures and TT status would 
yield improved mortality risk profiles. This is even more 
intriguing, given the increasing body of evidence sug-
gesting low TT concentrations as a meaningful biomark-
er of pre-existing metabolic disturbances and adverse 
cardiovascular risk factor profiles  [11–13] . Therefore, we 
used data from the population-based Study of Health in 
Pomerania (SHIP) including 1,822 men with long term 
follow-up, to explore the direct effects of kidney dysfunc-
tion, albuminuria and their combination on all-cause 
and cardiovascular mortality, and to investigate if a com-
bined assessment of CKD measures and TT status would 
yield improved mortality risk profiles.
 Methods 
 Study Population 
 SHIP is a population-based cohort study in West Pomerania, a 
region in northeastern Germany. Details on the SHIP study de-
sign, recruitment, and procedures have been published previously 
 [14] . The net sample (without migrated or deceased persons) com-
prised 6,265 eligible subjects, whereof 4,308 finally participated 
(response rate 68.7%). All participants gave written informed con-
sent. The study conformed to the ethical guidelines of the 1975 
Declaration of Helsinki, as reflected in an a priori  approval by the 
local Ethics Committee of the University of Greifs wald. From the 
2,116 male baseline participants, we excluded men due to unmea-
sured concentrations of serum creatinine (n = 12), urine creatinine 
(n = 19), urine albumin (n = 149), or TT (n = 76). We also excluded 
men with measured urine creatinine concentrations  ! 1.0 mmol/l 
or  1 100 mmol/l (n = 29), adenomas (n = 2), or self-reported intake 
of sex steroids (Anatomical Therapeutic Chemical, ATC, code 
G03; n = 2), testosterone 5  reductase inhibitors (ATC code 
G04CB; n = 4), or sex steroid antagonists (ATC code L02B; n = 1). 
The final study population comprised 1,822 men.
 Clinical Evaluation 
 Computer-assisted personal interviews assessed information 
regarding age, smoking (current, former, and never smokers), as 
well as subjects’ self-reported medical history of diabetes mellitus. 
After a resting period of at least 5 min, systolic and diastolic blood 
pressure was measured three times at the right arm of seated sub-
jects by use of an oscillometric digital blood pressure monitor 
(HEM-705CP; Omron Corporation, Tokyo, Japan). The interval 
between the readings was 3 min. The mean of the second and 
third measurements was calculated and used for the present anal-
yses. Hypertension was defined by systolic blood pressure or dia-
stolic blood pressure of  6 140 and  6 90 mm Hg, respectively, or 
use of antihypertensive medication (ATC codes: C02, C03, C04, 
C07, C08, or C09). Waist circumference (WC) was measured to 
the nearest 0.1 cm using an inelastic tape midway between the 
lower rib margin and the iliac crest in the horizontal plane, with 
the subject standing comfortably with weight distributed evenly 
on both feet.
 Laboratory Examinations 
 Non-fasting blood samples were taken from the cubital vein in 
the supine position between 07: 00 a.m. and 06: 00 p.m. and pre-
pared for immediate analysis or for storage at –80   °   C for further 
analysis. Serum creatinine concentrations were determined with 
the Jaffé method (Hitachi 717; Roche Diagnostics, Germany), and 
the estimated glomerular filtration rate (eGFR) was calculated us-
ing the Modification of Diet in Renal Disease equation  [15] : eGFR 
(ml/min/1.73 m 2 ) = 186  ! serum creatinine (mg/dl) –1.154  ! age 
(years) –0.203 . Kidney dysfunction was defined as eGFR  ! 60 ml/
min/1.73 m 2 . Concentrations of urine albumin and creatinine were 
determined on a Behring Nephelometer (Siemens BN albumin; 
Siemens Healthcare, Marburg, Germany) and a Hitachi 717 (Roche 
Diagnostics), respectively. The urinary albumin-creatinine ratio 
(UACR) following the equation: UACR (mg/mmol) = urine albu-
min concentration (mg/l)/urine creatinine concentration (mmol/l) 
was used as a measure of albumin excretion. Albuminuria was de-
fined as an UACR of  6 2.5 mg/mmol  [16] . According to the Kidney 
Disease Outcomes Quality Initiative guidelines, CKD was defined 
as presence of kidney dysfunction and/or albuminuria  [17] .
 Low-density lipoprotein cholesterol (LDL-C) was measured 
by applying a precipitation procedure using dextran sulphate 
(Immuno, Heidelberg, Germany) on an Epos 5060 (Eppendorf, 
Hamburg, Germany). TT concentrations were measured from 
frozen serum aliquots using competitive chemiluminescent en-
zyme immunoassays on an Immulite 2500 analyzer (Siemens 
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Healthcare Medical Diagnostics, Bad Nauheim, Germany). Mea-
surements were carried out from December 2005 to January 2006. 
The inter-assay coefficient of variation was 13.2% with a system-
atic deviation of +2.3% at the 3.2 nmol/l level, and 8.9% with a 
systematic deviation of +0.24% at the 22.5 nmol/l level  [18] . Low 
TT concentrations were defined according to the 10th percentile 
in every 10-year age group.
 Mortality Follow-Up 
 During 17,243 person-years (median, 9.9 years; 25th, 9.2; 75th, 
10.7) of follow-up, 282 individuals (15.5%) died, reflecting an over-
all crude mortality rate of 16.4 deaths per 1,000 person-years. In-
formation on vital status was collected from population registries 
at annual intervals from time of enrollment into the study through 
December 15, 2009. Subjects were censored at either death or loss 
to follow-up and the number of months between baseline exami-
nation and censoring was used as follow-up length. Death certifi-
cates were requested from the local health authority at the place of 
death. Causes of deaths were coded by a certified nosologist ac-
cording to the International Classification of Diseases, 10th revi-
sion (ICD-10). Additionally, 2 internists (H.W. and M.D.) indepen-
dently validated the underlying cause of death, and performed a 
joint reading in cases of disagreement. A third internist (H.V.) fi-
nally decided in cases of still existing disagreement. Cardiovascu-
lar mortality comprised the ICD-10 codes I10–I79 (I10–I15 hyper-
tensive diseases, I20–I25 ischemic heart diseases, I26–I28 pulmo-
nary heart disease and diseases of pulmonary circulation, I30–I52 
other forms of heart disease, I60–I69 cerebrovascular diseases, 
and I70–I79 diseases of arteries, arterioles and capillaries).
 Statistical Analyses 
 Baseline characteristics of the study population are expressed 
as median and interquartile range for qualitative data and as per-
cent values for qualitative data as indicated. In a first step, we used 
multivariable Cox proportional hazards regression models ad-
justed for age, WC, smoking, diabetes mellitus, hypertension, and 
LDL-C concentrations to analyze the associations between mea-
sures of impaired kidney function and all-cause as well as cardio-
vascular mortality. We used an established threshold at the age of 
70 years to repeat the conducted models stratified by age  [19] . We 
graphically explored log-log plots to satisfy the proportional haz-
ards assumption. To evaluate possible non-response bias due to 
missing data, we additionally included inverse probability weights 
into the multivariable models calculated with respect to baseline 
information regarding age, WC, physical activity, diabetes mel-
litus, and hypertension  [20] . To account for potentially confound-
ing effects of acute illness, sensitivity analyses were performed by 
excluding first-year decedents (n = 17). Further sensitivity analy-
ses included the additional adjustment for blood sampling time 
and statin use (ATC code C10AA), both factors known to affect 
GFR and albumin excretion  [21] , as well as testosterone concen-
trations  [22] .
 In a second step, we reassessed the multivariable Cox models 
stratified by TT status. Kaplan-Meier analyses were graphed and 
survival curves compared by log-rank test. To avoid arbitrariness 
in the definition of low TT concentrations, we also applied alter-
native cutoffs. We tested multiplicative interaction terms for 
eGFR, UACR, and CKD with continuous TT concentrations: (1) 
in parsimonious bivariate models including the respective inter-
action, (2) additionally adjusted for age, and (3) in fully adjusted 
multivariable models. A significant interaction term (p  ! 0.05) 
indicates that the effect of one exposure (low TT) on mortality 
varies according to the value of the second exposure (eGFR, 
UACR, or CKD, respectively). Furthermore, we aimed to compare 
the predictive ability between multivariable Cox models without 
and with continuous TT concentrations using receiver-operating 
characteristic (ROC) curves, C-statistics, and the integrated dis-
crimination improvement (IDI)  [23] . The IDI is based on con-
tinuous differences in the predicted risk between the two esti-
mated models based on multivariable logistic regression models 
that examined deaths through 10-years of follow-up. Hazard ra-
tios (HR) were calculated with 95% confidence intervals (95% CI), 
and two-sided probability values  ! 0.05 were considered statisti-
cally significant. All statistical analyses were performed using 
Stata 11.0 (Stata Corporation, College Station, Tex., USA).
 Results 
 Baseline data for the study population are given in  ta-
ble 1 . The overall prevalence of kidney dysfunction, albu-
minuria, and CKD was 6.4, 19.1, and 22.8%, respectively. 
Median TT concentrations were significantly lower in 
men with kidney dysfunction (14.6 nmol/l), albuminuria 
(15.9 nmol/l), and CKD (15.8 nmol/l) compared to men 
without these conditions (p  ! 0.05). Prevalence estimates 
for low TT concentrations ranged from 12.0% among 
men with kidney dysfunction to 13.2% (albuminuria) 
and 14.1% (CKD). Graphed Kaplan-Meier analyses for 
all-cause and cardiovascular mortality indicate that men 
Table 1.  Baseline characteristics of the study population
N 1,822
Sex male
Age, years 51.8 (37.2; 65.4)1
WC, cm 95.5 (87.5; 103.2)1
Serum creatinine, mmol/l 90.0 (83.3; 98.4)1
eGFR, ml/min/1.73 m2 83.2 (73.8; 92.9)1
Urine creatinine, mmol/l 10.0 (6.8; 13.8)1
Urine albumin, mg/l 8.5 (4.8; 18.5)1
Kidney dysfunction, % 6.4
Albuminuria, % 19.1
CKD, % 22.8
Serum TT, nmol/l 15.9 (12.5; 19.9)1
Low TT (<age-dependent 10th percentile), % 10.2
LDL-C, mmol/l 3.6 (2.8; 4.3)1
Diabetes mellitus, % 8.8
Hypertension, % 64.4
Current smoking, % 33.4
1  Median (25th; 75th percentile).
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with kidney dysfunction, albuminuria, or CKD had sig-
nificantly shorter survival times (p  ! 0.001) compared to 
men without these conditions (graphs not shown). Mul-
tivariable Cox models presented in  table 2 indicate an in-
creased all-cause mortality risk from kidney dysfunction 
(HR, 1.40; 95% CI, 1.02–1.92), albuminuria (HR, 1.38; 
95% CI, 1.06–1.79), and CKD (HR, 1.42; 95% CI, 1.09–
1.84), respectively. Of the 270 men with available death 
certificates, 89 (33.0%) died from cardiovascular causes. 
After multivariable adjustment, only kidney dysfunction 
(HR, 2.01; 95% CI, 1.21–3.34) was associated with in-
creased risk of cardiovascular mortality independent of 
traditional risk factors ( table 2 ). In age-stratified analyses, 
we found men aged 29–69 to be particularly responsive 
to the revealed association of kidney dysfunction with 
all-cause (HR, 2.19; 95% CI, 1.34–3.59) and cardiovascu-
lar mortality (HR, 4.34; 95% CI, 1.91–9.87).
 Sensitivity analyses slightly decreased the revealed es-
timates by the exclusion of first-year decedents and the 
inclusion of inverse probability weights, respectively ( ta-
ble 2 ), whereas the additional adjustment for blood sam-
pling time and statin use showed no overall impact on the 
revealed estimates (data not shown). Interaction terms for 
eGFR, UACR, and CKD suggested overlapping interrela-
tionships in bivariate (p  ! 0.001,  ! 0.001, and 0.040, re-
spectively) and age-adjusted models (0.046, 0.001, and 
Table 2. Association of measures of impaired kidney function with all-cause and cardiovascular mortality
Models Kidney dysfunction Albuminuria CKD 
all-cause
mortality
cardiovascular
mortality
all-cause
mortality
cardiovascular
mortality
all-cau se
mortality
cardiovascular
mortality
1 Age-adjusted model 1.49 (1.09–2.03)* 2.16 (1.32–3.52)* 1.46 (1.14–1.88)* 1.40 (0.90–2.17) 1.51 (1.18–1.92)* 1.74 (1.12–2.68)*
2 Multiple-adjusted model 1.40 (1.02–1.93)* 2.01 (1.21–3.34)* 1.38 (1.06–1.79)* 1.18 (0.74–1.89) 1.42 (1.09–1.84)* 1.46 (0.92–2.33)
29–69 years (n = 1,564) 2.19 (1.34–3.59)* 4.34 (1.91–9.87)* 1.62 (1.14–2.31)* 1.30 (0.63–2.66) 1.66 (1.17–2.35)* 1.91 (0.97–3.74)
70–79 years (n = 258) 1.13 (0.75–1.73) 1.45 (0.76–2.77) 1.19 (0.80–1.78) 1.08 (0.57–2.04) 1.22 (0.81–1.82) 1.13 (0.58–2.18)
2 + Non-response weights 1.34 (0.98–1.85) 2.10 (1.25–3.53)* 1.32 (1.01–1.73)* 1.26 (0.78–2.03) 1.36 (1.04–1.77)* 1.55 (0.97–2.48)
2 Excluding first-year deaths 1.32 (0.94–1.83) 1.72 (1.01–2.93)* 1.37 (1.05–1.81)* 1.28 (0.79–2.06) 1.34 (1.03–1.76)* 1.36 (0.84–2.19)
M ultiple-adjusted model included adjustment for age, WC, diabetes mellitus, hypertension, smoking (3 categories), and LDL-C concentrations.
* p < 0.05. Figures represent hazard ratios (95% CI).
Table 3.  Association of measures of impaired kidney function with all-cause mortality stratified by low TT concentrations
Models Kidney dysfunction Albuminuria CKD 
TT ≤10th TT >10th TT ≤10th TT >10th TT ≤10th TT >10th
All-cause mortality
1 Age-adjusted model 2.80 (1.33–5.85)* 1.32 (0.94–1.86) 1.01 (0.51–1.99) 1.49 (1.14–1.95)* 1.37 (0.68–2.77) 1.48 (1.13–1.92)*
2 Multiple-adjusted model 2.52 (1.08–5.85)* 1.26 (0.89–1.80) 0.58 (0.24–1.41) 1.46 (1.11–1.94)* 1.00 (0.43–2.32) 1.43 (1.08–1.89)*
29–69 years 17.01 (3.90–74.1)* 1.67 (0.94–2.99) 0.67 (0.17–2.59) 1.73 (1.19–2.52)* 1.96 (0.58–6.68) 1.64 (1.13–2.38)*
70–79 years 1.24 (0.31–5.01) 1.13 (0.72–1.80) 0.37 (0.09–1.48) 1.26 (0.82–1.94) 0.49 (0.14–1.72) 1.26 (0.81–1.95)
2 + Non-response weights 3.82 (1.63–8.94)* 1.15 (0.81–1.64) 0.50 (0.21–1.21) 1.40 (1.05–1.86)* 0.90 (0.38–2.14) 1.35 (1.02–1.79)*
2 Excluding first-year deaths 2.20 (0.93–5.23)* 1.19 (0.82–1.73) 0.54 (0.21–1.35) 1.48 (1.10–1.97)* 0.96 (0.41–2.26) 1.36 (1.02–1.81)*
Cardiovascular mortality
1 Age-adjusted model 3.97 (1.31–12.01)* 1.87 (1.08–3.24)* 0.97 (0.33–2.88) 1.36 (0.83–2.22) 2.14 (0.62–7.36) 1.57 (0.98–2.53)
2 Multiple-adjusted model 2.93 (0.88–9.86) 1.63 (0.92–2.90) 0.30 (0.05–1.66) 1.21 (0.72–2.02) 1.44 (0.30–6.94) 1.30 (0.79–2.16)
29–69 years 12.64 (0.51–314.2) 2.89 (1.10–7.59)* 0.47 (0.03–7.52) 1.37 (0.63–3.02) 3.07 (0.24–38.6) 1.66 (0.79–3.48)
70–79 years 2.97 (0.41–21.45) 1.23 (0.59–2.56) 0.13 (0.01–1.76) 1.11 (0.55–2.26) 0.45 (0.04–4.47) 1.03 (0.50–2.14)
2 + Non-response weights 4.58 (1.14–18.32)* 1.62 (0.90–2.90) 0.46 (0.08–2.51) 1.25 (0.74–2.11) 1.67 (0.32–8.84) 1.34 (0.81–2.23)
2 Excluding first-year deaths 2.94 (0.86–9.86) 1.32 (0.71–2.43) 0.30 (0.05–1.66) 1.32 (0.79–2.23) 1.44 (0.30–6.94) 1.18 (0.70–2.00)
Mu ltiple-adjusted model included adjustment for age, WC, diabetes mellitus, hypertension, smoking (3 categories), and LDL-C concentrations. Low 
TT concentrations were defined according to the 10th percentile in every 10-year age group. * p < 0.05. Figures represent hazard ratios (95% CI).
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0.022, respectively), but not in multivariable models 
(0.120, 0.152, and 0.111, respectively). The additional in-
clusion of continuous TT concentrations to the multi-
variable model associating kidney dysfunction, albumin-
uria, and CKD with increased all-cause and cardiovascu-
lar mortality showed no significant improvement (p  ! 
0.05) in the overall predictive ability, as indicated by ROC 
analyses, C-statistics, and IDI.
 In a next step, we used TT concentrations to conduct 
stratified analyses. Kaplan-Meier analyses depicted in 
 figure 1 show that the subgroup of men with kidney dys-
function, albuminuria, or CKD, together with low TT 
concentrations experienced the shortest survival time 
(log-rank test, p  ! 0.001). Multivariable Cox models pre-
sented in  table 3 revealed that men with kidney dysfunc-
tion and low TT concentrations had a more than 2-fold 
increased all-cause mortality risk (HR, 2.52; 95% CI, 
1.08–5.85). In contrast, kidney dysfunction was not as-
sociated with a higher mortality risk among men with 
higher TT concentrations (HR, 1.26; 95% CI, 0.89–1.80). 
When we used alternative cutoffs for the definition of low 
TT concentrations, we found comparable risk estimates 
for the association of kidney dysfunction with all-cause 
mortality ( fig. 2 ). With regard to albuminuria and CKD, 
refined mortality risk stratification by using TT status 
did not reveal any substantial deviations from the previ-
ous, unstratified estimates ( table 3 ). We did not detect any 
association of kidney dysfunction, albuminuria, or CKD 
with increased cardiovascular mortality risk after multi-
variable adjustment ( table 3 ). The additional inclusion of 
non-response weights considerably increased the re-
vealed estimates for the association of kidney dysfunc-
tion with all-cause and cardiovascular mortality risk 
among men with low TT concentrations, while the exclu-
sion of 17 first-year decedents showed no major impact 
on the revealed multivariable estimates ( table 3 ).
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 Fig. 1. Kaplan-Meier survival curves for men with and without 
kidney dysfunction, albuminuria, and CKD stratified by low and 
higher TT concentrations. Survival times differed significantly 
between groups (log-rank test, p  ! 0.001). 
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HR (95% CI)
TT ≤6.9 nmol/l
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TT ≤10.4 nmol/l
TT ≤11.7 nmol/l
 Fig. 2. Estimates for the association of kidney dysfunction with 
all-cause mortality risk by different cutoffs for the definition of 
low TT concentrations. Models were adjusted for age, WC, diabe-
tes mellitus, hypertension, smoking (3 categories), and LDL-C 
concentrations. 
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 Discussion 
 The present population-based study among 1,822 men 
demonstrates that kidney dysfunction is associated with 
all-cause mortality and cardiovascular mortality after 
adjustment for traditional risk factors. Furthermore, we 
reported improved mortality risk stratification through 
the combined assessment of eGFR and TT concentra-
tions. Although several previous studies have reported 
associations of kidney dysfunction and albuminuria with 
mortality risk in the general population, the present pop-
ulation-based investigation is the first one to demonstrate 
how the mortality risk attributable to kidney dysfunction 
varies as a function of low TT concentrations.
 In a first step, we analyzed the independent and com-
bined associations of kidney dysfunction and albumin-
uria with all-cause and cardiovascular mortality. While 
we found all three conditions predictive of all-cause mor-
tality, only kidney dysfunction was associated with high-
er cardiovascular mortality. These findings are consis-
tent with a recent meta-analysis of 21 general population 
cohorts  [3] and other large-scale community-based stud-
ies  [4, 24] . The absence of associations of albuminuria and 
CKD with cardiovascular mortality after multivariable 
adjustment in our study is most likely explained by the 
comparably low number of cardiovascular deaths and by 
differences in the categorizations used for the definition 
of albuminuria. Furthermore, our findings suggest eGFR 
and UACR as biomarkers of mortality risk with a higher 
prognostic significance particularly among middle-aged 
men (29–69 years), as we were not able to detect these as-
sociations in the elderly (70–79 years).
 Next, we considered serum TT concentrations for 
prevalence estimates, further risk stratification, and po-
tential risk prediction improvements. In comparison 
with previous prevalence estimates (TT  ! 10.0 nmol/l) of 
52% among male dialysis patients  [10] or 44% among men 
with end-stage renal disease  [9] , our estimated prevalence 
of 14% is lower because it is based on non-dialysis indi-
viduals with mild kidney dysfunction from the general 
population. Alternatively or in addition, our applied age-
specific cutoff for the definition of low TT may help to 
explain the different prevalence estimates. Recent guide-
lines recommended cutoffs between 9.8 and 10.4 nmol/l 
(280 and 300 ng/dl, respectively) to define the lower lim-
it of normal TT concentrations for healthy young men, 
but lacked consensus on the TT threshold in older men 
 [25] . In contrast to fixed cutoffs, age-specific percentile 
cutoffs may reflect the existence of different serum TT 
concentration thresholds below which metabolic changes 
related to low TT may occur  [26] . Furthermore, our sen-
sitivity analyses with alternative cutoffs for the definition 
of low TT showed comparable associations with all-cause 
mortality in men with kidney dysfunction, proving the 
validity of our findings.
 Using TT concentrations to refine mortality risk strat-
ification, we identified men with kidney dysfunction and 
low TT concentrations as high-risk individuals with a 
more than 2-fold increased risk of all-cause mortality. We 
also found an age-related attenuation in the combined 
risk profile in men aged 29–69 years. With regard to al-
buminuria and CKD, mortality risk stratification by TT 
status did not reveal any significant risk profiles. Recent 
data suggest that TT may be a ‘biomarker of good health’ 
 [27] . TT concentrations have been shown to fall in asso-
ciation with various different conditions such as obesity, 
metabolic syndrome, or dyslipidemia, and change over 
time as well as in response to changing health status  [28] . 
Thus, it seems plausible that low TT concentrations are 
related to increased morbidity. Along this line, there is 
growing evidence showing that low TT concentrations 
are associated with the development of metabolic syn-
drome  [12] , dyslipidemia  [29] , and increased health care 
utilization  [30] . Independent associations of low TT con-
centrations with increased mortality risk were previously 
reported from different prospective cohort studies in-
cluding ours  [8, 31–33] . Overall, our finding that low TT 
concentrations show an additive effect on the association 
of kidney dysfunction with all-cause mortality is not sur-
prising, since multisystemic disorders (that are widely 
prevalent in the aging male) such as CKD, metabolic syn-
drome, or sarcopenia are likely to be associated with hor-
monal dysregulation. But according to a cross-sectional 
study among 1,470 men from the general US population, 
low TT concentrations are not directly associated with 
CKD  [34] . This study suggests low TT is a surrogate pa-
rameter of disease severity rather than a causal CKD risk 
factor.
 Experimental results suggest that TT may promote de-
cline in renal function  [35, 36] . Castration in male rats for 
example, completely prevents reductions in GFR and glo-
merular injury  [35] , whereas the acute infusion of testos-
terone causes renal vasodilation with increases in GFR 
 [36] . The recently stopped TOM (Testosterone in Older 
Men with Mobility Limitations) trial among elderly men 
(mean age 74 years) reported that testosterone treatment 
was associated with an increased risk of adverse cardio-
vascular events  [37] . For the interpretation of these re-
sults, it must be mentioned that the starting doses in the 
TOM trial were higher than those recommended by the 
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manufacturer, and the treatment goal (34.7 nmol/l) was 
considerably higher than that recommended by the En-
docrine Society in these patients (13.9–17.4 nmol/l)  [37] . 
Against this background, the high rate of adverse cardio-
vascular events in the TOM trial is suggestive of over-
supplementation. However, there is a lack of rigorous 
clinical trials examining the effects of chronic testoster-
one on cardiovascular-renal disease risk  [36] . It may still 
be possible that exogenous testosterone affects CKD pro-
gression and related symptoms, although there are insuf-
ficient data to support this hypothesis at present. Accord-
ingly, a recent review of 51 testosterone trials with various 
outcomes concluded that the current evidence about the 
safety of testosterone treatment in men is of low quality 
and limited by short follow-up times  [38] .
 To evaluate the predictive utility of low TT concentra-
tions, we included continuously distributed TT concen-
trations into the multivariable model predicting mortal-
ity from CKD but failed to meaningfully alter the predic-
tive ability of the multivariable model, as evidenced by 
small changes in the area under the ROC curve, C statis-
tic, and IDI. A reasonable finding, given the powerful tra-
ditional risk factors including age, smoking, hyperten-
sion, dyslipidemia, and diabetes mellitus that were al-
ready in the model  [23] . Further sensitivity analyses 
excluding first-year deaths yielded similar estimates, sug-
gesting that the association between kidney dysfunction, 
low TT, and all-cause mortality was not simply due to 
acute illness and increased levels of systemic inflamma-
tion.
 Given the revealed associations of kidney dysfunction 
and low TT concentrations with increased mortality risk, 
we assumed a synergistic relationship such that the pres-
ence of low TT enhances the risk of mortality attributable 
to kidney dysfunction. When we investigated this hy-
pothesis by analyzing a parsimonious model including 
terms for low TT, eGFR, and their interaction, the inter-
action term was statistically significant, even after age 
adjustment. But the interaction term lost statistical sig-
nificance in the multivariable model, suggesting that 
while low TT and kidney dysfunction are both associated 
with increased mortality risk, they are primarily additive 
rather than synergistic and may even share some similar 
risk factor profiles. Accordingly, we detected this additive 
effect in combined risk stratification analyses, showing 
that the subgroup of men with kidney dysfunction and 
low TT concentrations had the highest mortality risk, 
even after adjustment for major confounders.
 Potential limitations of the present investigation may 
arise from the single spot measurement of TT and uri-
nary albumin. Because of the variability in urinary albu-
min excretion, at least two specimens collected within a 
3- to 6-month period would have been desirable to quan-
tify urinary albumin excretion more accurately. In the 
absence of repeated measurements, it is generally recom-
mended to use the UACR  [39] . Furthermore, single mea-
surements of eGFR  [40] and TT concentrations  [41] have 
been shown to be of prognostic value in previous epide-
miological studies. The major strength of our study is the 
large population-based sample of men with a broad age 
range from 20 to 79 years, enabling refined risk stratifica-
tion based on TT status. Furthermore, we were able to 
comprehensively evaluate the independent and com-
bined associations of reduced eGFR and albuminuria 
with all-cause as well as cardiovascular mortality.
 Our findings suggest that the combined assessment of 
measures of impaired kidney function together with TT 
concentrations might help to detect increased mortality 
risk associated with CKD, even in the general population. 
Based on our main finding that the combined risk pro-
files considerably improved mortality risk stratification, 
our results offer the potential to facilitate the appropriate 
recognition and screening of high-risk individuals for the 
application of individualized treatment plans. However, 
further research is necessary to prove whether TT re-
placement therapy indeed reduces progression of CKD or 
protects against CKD-related mortality risk.
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